Nationwide COVID-OUT treatment trial with ivermectin is underway
Phoenix Herald
23 Jul 2021, 10 GMT+10
An ongoing COVID-19 clinical trial studying the outpatient use of metformin, a generic medication for type 2 diabetes, has expanded and will now be the nation s first to include fluvoxamine, an antidepressant, and ivermectin, an antiparasitic, as possible treatment options to prevent hospitalization and long COVID.
Led by the University of Minnesota Medical School, the multi-site clinical trial received new support $1 million from the Rainwater Charitable Foundation and $500,000 from Fast Grants to expand the study, which is also the first randomized clinical trial for COVID-19 in the world to include pregnant women.
E-Mail
MINNEAPOLIS/ST. PAUL (05/25/2021) An ongoing COVID-19 clinical trial studying the outpatient use of metformin, a generic medication for type 2 diabetes, has expanded and will now be the nation s first to include fluvoxamine, an antidepressant, and ivermectin, an antiparasitic, as possible treatment options to prevent hospitalization and long COVID.
Led by the University of Minnesota Medical School, the multi-site clinical trial received new support - $1 million from the Rainwater Charitable Foundation and $500,000 from Fast Grants - to expand the study, which is also the first randomized clinical trial for COVID-19 in the world to include pregnant women.
The clinical trial launched after U of M Medical School researchers identified, through computer modeling and observational studies, that outpatient metformin use may decrease the likelihood of dying from or being hospitalized for COVID-19. Their research was published in the Journal of Medical Virology and in The Lan